Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TRPM8 | Q7Z2W7 | 8/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.54 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.54 |
| ▸ | LMNA | P02545 | 4/20 | 0.49 |
| ▸ | MAPT | P10636 | 2/20 | 0.49 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.49 |
| ▸ | HTT | P42858 | 1/20 | 0.45 |
| ▸ | NPC1 | O15118 | 1/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.44 |
| ▸ | CACNA1B | Q00975 | 1/20 | 0.44 |
| ▸ | APBA1 | Q02410 | 1/20 | 0.44 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15320779 | 0.92 | ALDH1A1 (0.49) | TRPM8ALDH1A1SMN1; SMN2LMNAMAPT | |
| SCHEMBL11781376 | 0.87 | ALDH1A1 (0.64) | TRPM8ALDH1A1SMN1; SMN2LMNAMAPT | |
| SCHEMBL11779197 | 0.87 | TRPM8 (0.50) | TRPM8ALDH1A1SMN1; SMN2LMNAMAPT | |
| Hydrochloric Acid SCHEMBL22797995 | 0.86 | TRPM8 (0.49) | TRPM8ALDH1A1SMN1; SMN2LMNAMAPT | |
| SCHEMBL11778764 | 0.83 | TRPM8 (0.47) | TRPM8ALDH1A1SMN1; SMN2LMNAMAPT | |
| Hydrochloric Acid SCHEMBL11781471 | 0.82 | TRPM8 (0.51) | TRPM8ALDH1A1SMN1; SMN2LMNAMAPT | |
| SCHEMBL11778757 | 0.81 | TRPM8 (0.53) | TRPM8ALDH1A1SMN1; SMN2LMNAMAPT | |
| SCHEMBL27884240 | 0.80 | SMN1; SMN2 (0.47) | TRPM8ALDH1A1SMN1; SMN2LMNAMAPT | |
| SCHEMBL12504795 | 0.79 | OPRD1 (0.42) | TRPM8ALDH1A1SMN1; SMN2 | |
| SCHEMBL19953681 | 0.78 | ALDH1A1 (0.44) | TRPM8ALDH1A1SMN1; SMN2LMNAMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7709503-B2 | Pyrrol derivatives with antibacterial activity | ASTRAZENECA AB (SE) | 2010-05-04 | — | — | US | disclosed |
| US-20060223801-A1 | Pyrrol derivatives with antibacterial activity | ASTRAZENECA AB (SE) | 2006-10-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060223801-A1 | Pyrrol derivatives with antibacterial activity | PEF1, PEPD, PELP1 | TRPM8 3951/4885ALDH1A1 976/4885SMN1; SMN2 3296/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.